Amgen (NASDAQ:AMGN) Shares Bought Rep. Virginia Foxx

Representative Virginia Foxx (R-North Carolina) recently bought shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on January 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on December 6th.

Representative Virginia Foxx also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 12/6/2024.
• Sold $50,001 - $100,000 in shares of Via Renewables NASDAQ: VIASP on 12/6/2024.
• Purchased $1,001 - $15,000 in shares of American Electric Power NASDAQ: AEP on 12/6/2024.
• Sold $15,001 - $50,000 in shares of FLEX LNG NYSE: FLNG on 12/6/2024.
• Sold $50,001 - $100,000 in shares of Pembina Pipeline NYSE: PBA on 12/6/2024.
• Purchased $1,001 - $15,000 in shares of Bristol-Myers Squibb NYSE: BMY on 12/6/2024.
• Sold $15,001 - $50,000 in shares of Ardmore Shipping NYSE: ASC on 12/6/2024.
• Sold $15,001 - $50,000 in shares of Alliance Resource Partners NASDAQ: ARLP on 12/6/2024.
• Purchased $1,001 - $15,000 in shares of Duke Energy NYSE: DUK on 12/6/2024.
• Sold $15,001 - $50,000 in shares of Energy Transfer NYSE: ET on 12/6/2024.

Amgen Price Performance

AMGN stock traded up $2.15 during trading on Thursday, hitting $264.21. 2,421,394 shares of the company's stock traded hands, compared to its average volume of 3,120,276. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The stock has a market capitalization of $142.02 billion, a price-to-earnings ratio of 33.83, a P/E/G ratio of 2.91 and a beta of 0.56. The business has a fifty day simple moving average of $280.24 and a 200 day simple moving average of $309.15. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts' consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter last year, the firm earned $4.96 EPS. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 19.53 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.60%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is currently 121.90%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Lantz Financial LLC grew its position in shares of Amgen by 5.1% in the 2nd quarter. Lantz Financial LLC now owns 1,779 shares of the medical research company's stock worth $556,000 after buying an additional 87 shares during the last quarter. Private Advisor Group LLC increased its position in shares of Amgen by 17.4% during the second quarter. Private Advisor Group LLC now owns 60,383 shares of the medical research company's stock worth $18,867,000 after purchasing an additional 8,954 shares in the last quarter. Umpqua Bank lifted its holdings in shares of Amgen by 2.5% during the 2nd quarter. Umpqua Bank now owns 2,047 shares of the medical research company's stock valued at $640,000 after purchasing an additional 50 shares during the last quarter. Strategic Financial Concepts LLC acquired a new stake in shares of Amgen in the 2nd quarter worth $26,000. Finally, Asset Dedication LLC boosted its position in shares of Amgen by 9.5% in the 2nd quarter. Asset Dedication LLC now owns 19,091 shares of the medical research company's stock worth $5,965,000 after purchasing an additional 1,654 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Royal Bank of Canada decreased their price target on Amgen from $360.00 to $330.00 and set an "outperform" rating on the stock in a report on Wednesday, November 27th. TD Cowen raised their target price on shares of Amgen from $381.00 to $383.00 and gave the stock a "buy" rating in a report on Monday, October 21st. William Blair reaffirmed an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Sanford C. Bernstein began coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an "outperform" rating and a $380.00 price objective on the stock. Finally, UBS Group decreased their price objective on shares of Amgen from $335.00 to $326.00 and set a "neutral" rating for the company in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $317.30.

About Representative Foxx

Virginia Foxx (Republican Party) is a member of the U.S. House, representing North Carolina's 5th Congressional District. She assumed office on January 3, 2005. Her current term ends on January 3, 2025. Foxx (Republican Party) is running for re-election to the U.S. House to represent North Carolina's 5th Congressional District. She declared candidacy for the 2024 election. Prior to her election to the U.S. House, Foxx served as a member of the North Carolina State Senate as well as deputy secretary for management for North Carolina. Foxx was born in New York, New York. She earned a B.A. and M.A.C.T. from the University of North Carolina, Chapel Hill, in 1968 and 1972, respectively, and an Ed.D. from the University of North Carolina, Greensboro, in 1985. Foxx worked as an instructor at Caldwell Community College in Hudson, NC, and an instructor and assistant dean at Appalachian State University in Boone, NC. She owned a landscape nursery and served as Deputy Secretary for Management at the North Carolina Department of Administration.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.